Wednesday, March 25, 2026
Facebook Linkedin Twitter
HomeTagsBronchiolitis obliterans syndrome

bronchiolitis obliterans syndrome

Healthcare

Renovion Receives FDA Fast Track Designation for ARINA-1 for the Prevention of BOS Progression in Lung Transplant Patients

Business Wire -
Renovion, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARINA-1 for the prevention of bronchiolitis obliterans...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics

Load more
ReadMagazine © | All rights reserved |Contact Us | Privacy Policy| Become A Guest Writer | Advertise with Us | Terms & Conditions